IXAZOMIB

Course overview

IXAZOMIB, A SECOND-GENERATION PROTEASOME INHIBITOR, IS USED PRIMARILY IN THE TREATMENT OF MULTIPLE MYELOMA. THIS ACTIVITY OUTLINES THE MECHANISM OF ACTION, INDICATIONS, AND CONTRAINDICATIONS FOR IXAZOMIB AS A VALUABLE AGENT IN TREATING MULTIPLE MYELOMA. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS PERTINENT FOR MEMBERS OF AN INTERPROFESSIONAL TEAM MANAGING THE CARE OF PATIENTS WITH MULTIPLE MYELOMA AND ITS RELATED CONDITIONS AND SEQUELAE.